Content Analysis of US FDA Warning Letters Issued to Compounding Pharmacies Regarding Violations of Current Good Manufacturing Practices Between 2017 and 2022.
Isra DmourPublished in: Journal of pharmaceutical innovation (2022)
The online version contains supplementary material available at 10.1007/s12247-022-09692-4.